Compounds

Compound Name Developer(s)
1599 Microbiotix, Inc.
2HRZE 2HR
Actinomycete metabolites
Adamantanids
ATP Synthesis Inhibitors TB Alliance, University of Auckland
Auranofin The Aurum Institute NPC, Calibr, The Scripps Research Institute
AZD5847 AstraZeneca
Bedaquiline Janssen Research & Development, LLC
Benzofuroxan São Paulo State University (UNESP)
Bi-functional Molecules
Bortezomib SPRINT TB (National University of Singapore)
BTZ-043 University of Munich, Hans-Knöll Institute, Jena, German Center for Infection Research (DZIF)
CC-11050 The Aurum Institute NPC
Celecoxib
Celecoxib WBA
Clofazimine Novartis
Contezolid (MRX-4/MRX-1) MicuRx Pharmaceuticals, Inc.
CPZEN-45
Cyclopeptides
DC-159a
Delamanid Otsuka Pharmaceutical Development & Commercialization, Inc.
Delpazolid (LCB01-0371) LegoChem Biosciences, Inc.
DNA metabolism
DprE Inhibitors
DprE1 Inhibitors Calibr, The Scripps Research Institute
EMB
Energy Metabolism Inhibitors
Everolimus The Aurum Institute NPC
Faropenem WBA
Folate Biosynthesis Inhibitors
Gatifloxacin
GSK 070, GSK 3036656 GlaxoSmithKline
GSK-286 GlaxoSmithKline, TB Drug Accelerator
Gyrase B Inhibitor
GyrB Inhibitors
HE2000
HMG-CoA Reductase Inhibitors
Hsp65 DNA
Immunoxel
IMPDH Inosine monophosphate dehydrogenase inhibitors
Indazoles GlaxoSmithKline, TB Alliance
Indolcarboxamides TB Alliance
Indoles
InhA Inhibitor GSK-693
Inhibitors of DosRST signaling and persistence Michigan State University
Inhibitors of isoprenoid biosynthesis
Isoniazid
LeuRS inhibitors GlaxoSmithKline, Anacor Pharmaceuticals
Levofloxacin CDC TBTC, NIAID, NIH, DHHS, Boston University
Macozinone (MCZ, PBTZ-169) Nearmedic Plus LLC
Macozinone (MCZ, PBTZ-169) iM4TB - Innovative Medicines for Tuberculosis, Bill & Melinda Gates Foundation
Macrolides
Malate Synthase Inhibitors
Menaquinone Synthase Inhibitors
Meropenem / Clavulanate
Moxifloxacin TB Alliance
Moxifloxacin for Drug-Sensitive TB
MTopo
Mycobacterial Gyrase Inhibitors
Nitazoxanide Weill Medical College of Cornell University
Novel hit-lead programs
OPC-167832 Otsuka Pharmaceutical Development & Commercialization, Inc.
Optimized Background Regimen (OBR)
Phenotypic Hit-to-Lead
PKS13 Inhibitors
Pretomanid TB Alliance
Protein Splicing Inhibitors
Pyrazidamide TB Alliance
Pyrazinamide Analogs
Pyridomycin
Quinolone TBK-613
Rifabutin
Rifampicin St. George's Hospital University of London
Rifampicin PanACEA, EDCTP, NIAID, NIH, DHHS, USAID
Rifapentine CDC TBTC, Sanofi
Rifapentine
RNA Polymerase Inhibitors
Ruthenium (II) phosphine/diimine/picolinate complexes
SATB-082 Sanofi, TB Alliance
Spectinamide 1810 Microbiotix, Inc.
SPR-113
SPR720 Spero Therapeutics, LLC
SQ109 Sequella, Inc
SQ609 Sequella, Inc
SQ641
Sutezolid Sequella, Inc, TB Alliance
TB Respiratory Chain CSIR-Institute for Microbial Technology (IMTech), Johnson & Johnson
TB-47 Guangzhou Egg Biotechnology Co., Ltd.
TBA-354 TB Alliance
TBA-7371 TB Alliance
TBAJ-587, Diarylquinoline TB Alliance, University of Auckland
TBI-166 Institute of Materia Medica, CAMS & PUMC
TBI-223 TB Alliance, Institute of Materia Medica
Telacebec (Q203) Qurient Co., Ltd, Qurient Co. Ltd. / LLC "Infectex", a portfolio firm of Maxwell Biotech Venture Fund
TGF-B inhib +Cox 2 inhibitor
Thioridazine
TL1 Inhibitors
Trisubstituted benzimidazoles
Tryptanthrins
Ureas
Vitamin D3 The Aurum Institute NPC
Whole cell fragment screens
Whole Cell Hit-to Lead
Whole cell pathway screens
Whole-Cell Hit-to-Lead
Xanthones